340B Hearing Underscores Era Of Oversight, But Rolling Back Discount Program Doesn’t Look Likely
This article was originally published in RPM Report
Executive Summary
A House Energy & Commerce/Health Subcommittee hearing on the 340B drug discount program suggests there is bipartisan interest in legislation to enhance oversight of the program – but little interest in steps that might dramatically curtail the availability of discounted drugs to hospitals and other safety net providers.
You may also be interested in...
340B Meets Part B: Payment Proposal Unites Big Pharma and Safety Net Providers
The annual hunt for “pay-fors” is on: Congress is looking for offsets to pay for the cost of reversing physician payment cuts under Medicare. One idea would be to allow Medicare Part B to capture the prices of the 340B discount program. Providers who use 340B hate the idea – and manufacturers do too.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.